Literature DB >> 879814

Mycophenolic acid in the treatment of psoriasis: long-term administration.

R Marinari, R Fleischmajer, A H Schragger, A L Rosenthal.   

Abstract

Thirty five patients with psoriasis (plaque type 26, guttate 3, pustular 4, and erythrodermic 2) were treated with oral mycophenolic acid for a period ranging from 52 to 104 weeks. The average follow-up was 89 weeks, and the dose schedule ranged from 2,400 to 7,200 mg daily. Excellent response was noted in 20 patients, good in 13 patients, and poor in 2. The most common clinical side effects were in the gastrointestinal tract, namely, diarrhea, nausea, abdominal cramps, and soft stools. A high incidence of herpes simplex, herpes zoster, and a flu-like syndrome was noted. Laboratory abnormalities consisted of mild blood hemoglobin reduction, one case of leukopenia (3,9000 WBCs per cubic millimeter), two cases with thrombocytopenia and mild elevation of alkaline phosphatase. Mycophenolic acid appears as a promising drug for the treatment of severe psoriasis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 879814

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  5 in total

1.  [New immunosuppressive agents for treating psoriasis].

Authors:  S Ortiz-Urda; K Rappersberger
Journal:  Hautarzt       Date:  2003-02-18       Impact factor: 0.751

2.  In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages.

Authors:  J D Berman; H K Webster
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

3.  Application of Docking Analysis in the Prediction and Biological Evaluation of the Lipoxygenase Inhibitory Action of Thiazolyl Derivatives of Mycophenolic Acid.

Authors:  Evangelia Tsolaki; Phaedra Eleftheriou; Victor Kartsev; Athina Geronikaki; Anil K Saxena
Journal:  Molecules       Date:  2018-07-03       Impact factor: 4.411

4.  Effects of an immunosuppressive treatment on the rat prostate.

Authors:  Marta Grabowska; Karolina Kędzierska; Katarzyna Michałek; Sylwia Słuczanowska-Głąbowska; Maciej Grabowski; Małgorzata Piasecka; Andrzej Kram; Iwona Rotter; Aleksandra Rył; Maria Laszczyńska
Journal:  Drug Des Devel Ther       Date:  2016-09-12       Impact factor: 4.162

5.  Iatrogenic Kaposi sarcoma presenting as retiform purpura during treatment of bullous pemphigoid.

Authors:  Liesl Schroedl; Esther Kim; Mark D Hoffman
Journal:  JAAD Case Rep       Date:  2020-02-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.